What is a Group B Streptococcus (GBS) carrier?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is a GBS Carrier?

A GBS carrier is a pregnant woman who has Group B Streptococcus (Streptococcus agalactiae) colonizing her vaginal and/or rectal areas asymptomatically, identified through prenatal screening cultures, and who poses a risk for vertical transmission to her newborn during labor and delivery. 1

Definition and Colonization Pattern

  • GBS colonizes the lower genital tract of approximately 10-30% of pregnant women as an asymptomatic member of the gastrointestinal and vaginal flora. 2, 3

  • The gastrointestinal tract serves as the primary reservoir for GBS, with secondary spread to the genitourinary tract. 4, 2

  • Colonization is asymptomatic — carriers have no symptoms or signs of infection but harbor the bacteria in their rectovaginal area. 1, 3

Clinical Significance of Carrier Status

  • Newborns born to GBS carriers are at increased risk for early-onset GBS disease, which manifests as bacteremia, pneumonia, or meningitis within the first 7 days of life. 1

  • Women with GBS colonization are more than 25 times more likely to deliver infants with early-onset GBS disease compared to those with negative cultures. 2

  • Among infants who developed early-onset GBS disease, 88% were born to mothers who were detected prenatally as carriers. 1

Identification of Carriers

Optimal screening technique requires:

  • Timing: Cultures collected at 35-37 weeks' gestation provide the best correlation with intrapartum colonization status. 4, 1

  • Sites: Both vaginal introitus and rectum must be swabbed — vaginal and rectal specimens are more sensitive than cervical specimens alone. 1

  • Medium: Selective broth media (such as SBM broth or Lim broth) should be used for optimal detection. 1

  • When cultures are obtained ≤5 weeks before delivery, there is 100% concordance with intrapartum culture status (no false-negative or false-positive results). 1

Predictive Value and Duration of Carriage

  • A single positive GBS culture during pregnancy is 67% predictive of a positive culture at delivery, with estimated sensitivity of 70.0% and specificity of 90.4%. 1

  • The duration of GBS carriage is unpredictable — women can gain or lose colonization status over time, which is why screening timing is critical. 1

  • Only 7.4% of women with a negative culture at 26-28 weeks were found to carry GBS at delivery, emphasizing the importance of late-pregnancy screening. 1

Risk Stratification for Carriers

High-risk GBS carriers who require intrapartum antibiotic prophylaxis include those with:

  • Rupture of membranes >12 hours before delivery 1
  • Onset of labor or membrane rupture at <37 weeks' gestation 1
  • Intrapartum fever (temperature >99.5°F or >37.5°C) 1
  • Previous delivery of an infant with GBS disease 1
  • Multiple-gestation pregnancy 1
  • GBS bacteriuria during current pregnancy (indicates heavy colonization) 2

Common Pitfalls

  • Do not collect screening cultures from the cervix alone — this significantly reduces sensitivity compared to rectovaginal sampling. 1

  • Do not perform speculum examination for screening cultures — external swabs of the vaginal introitus and rectum are sufficient and more sensitive. 1

  • Carrier status does not mean active infection — these women are asymptomatic colonizers, not infected patients requiring treatment outside of labor. 1, 3

  • Screening too early in pregnancy (before 35 weeks) reduces predictive accuracy for colonization status at delivery. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Group B Streptococcus Infection and Preterm Birth

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Streptococcus agalactiae (Group B Streptococcus) Prevention and Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.